Lipocine is a biopharmaceutical company that develops oral drugs, with its lead product TLANDO licensed to partners for testosterone therapy. LPCN reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 21 | HC Wainwright & Co. | Reiterated | Hold |
Seasonality
How LPCN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in LPCN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LPCN is in one of them and how their past LPCN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LPCN in an article yet. Here's the latest on the wider market.
About Lipocine
Lipocine is a biopharmaceutical company based in Salt Lake City, United States. It uses its own technology to develop medicines taken by mouth, including drugs that the body does not absorb well in standard form. Its lead product, TLANDO, is an oral treatment for testosterone deficiency in adult men, and partner companies sell it to patients in several countries. The company also develops candidates for brain and nervous system conditions, liver disease, and hormone treatments.
- Headquarters
- Salt Lake City